Pugliese, D., Felice, C., Landi, R., Papa, A., Guidi, L., & Armuzzi, A. (2016). Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug Healthc Patient Saf.

Pugliese, Daniela, Carla Felice, Rosario Landi, Alfredo Papa, Luisa Guidi, and Alessandro Armuzzi. "Benefit–risk Assessment of Golimumab in the Treatment of Refractory Ulcerative Colitis." Drug Healthc Patient Saf 2016.

Pugliese, Daniela, et al. "Benefit–risk Assessment of Golimumab in the Treatment of Refractory Ulcerative Colitis." Drug Healthc Patient Saf 2016.